JP2013506715A5 - - Google Patents

Download PDF

Info

Publication number
JP2013506715A5
JP2013506715A5 JP2012533248A JP2012533248A JP2013506715A5 JP 2013506715 A5 JP2013506715 A5 JP 2013506715A5 JP 2012533248 A JP2012533248 A JP 2012533248A JP 2012533248 A JP2012533248 A JP 2012533248A JP 2013506715 A5 JP2013506715 A5 JP 2013506715A5
Authority
JP
Japan
Prior art keywords
nitrogen
oxygen
membered
ring
sulfur
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012533248A
Other languages
English (en)
Japanese (ja)
Other versions
JP6016635B2 (ja
JP2013506715A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/051517 external-priority patent/WO2011044157A1/en
Publication of JP2013506715A publication Critical patent/JP2013506715A/ja
Publication of JP2013506715A5 publication Critical patent/JP2013506715A5/ja
Application granted granted Critical
Publication of JP6016635B2 publication Critical patent/JP6016635B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012533248A 2009-10-06 2010-10-05 Pdk1インヒビターとして有用な複素環式化合物 Expired - Fee Related JP6016635B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24909509P 2009-10-06 2009-10-06
US61/249,095 2009-10-06
PCT/US2010/051517 WO2011044157A1 (en) 2009-10-06 2010-10-05 Heterocyclic compounds useful as pdk1 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016155272A Division JP2016188253A (ja) 2009-10-06 2016-08-08 Pdk1インヒビターとして有用な複素環式化合物

Publications (3)

Publication Number Publication Date
JP2013506715A JP2013506715A (ja) 2013-02-28
JP2013506715A5 true JP2013506715A5 (enExample) 2013-11-14
JP6016635B2 JP6016635B2 (ja) 2016-10-26

Family

ID=43857093

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2012533248A Expired - Fee Related JP6016635B2 (ja) 2009-10-06 2010-10-05 Pdk1インヒビターとして有用な複素環式化合物
JP2016155272A Withdrawn JP2016188253A (ja) 2009-10-06 2016-08-08 Pdk1インヒビターとして有用な複素環式化合物
JP2018106041A Pending JP2018145196A (ja) 2009-10-06 2018-06-01 Pdk1インヒビターとして有用な複素環式化合物
JP2020149736A Withdrawn JP2020203925A (ja) 2009-10-06 2020-09-07 Pdk1インヒビターとして有用な複素環式化合物
JP2022177407A Pending JP2023002840A (ja) 2009-10-06 2022-11-04 Pdk1インヒビターとして有用な複素環式化合物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2016155272A Withdrawn JP2016188253A (ja) 2009-10-06 2016-08-08 Pdk1インヒビターとして有用な複素環式化合物
JP2018106041A Pending JP2018145196A (ja) 2009-10-06 2018-06-01 Pdk1インヒビターとして有用な複素環式化合物
JP2020149736A Withdrawn JP2020203925A (ja) 2009-10-06 2020-09-07 Pdk1インヒビターとして有用な複素環式化合物
JP2022177407A Pending JP2023002840A (ja) 2009-10-06 2022-11-04 Pdk1インヒビターとして有用な複素環式化合物

Country Status (27)

Country Link
US (6) US9546165B2 (enExample)
EP (3) EP3070077B1 (enExample)
JP (5) JP6016635B2 (enExample)
KR (3) KR20120087936A (enExample)
CN (1) CN102665718B (enExample)
AR (2) AR078540A1 (enExample)
AU (3) AU2010303567B2 (enExample)
BR (1) BR112012007747B8 (enExample)
CA (1) CA2776690C (enExample)
CY (1) CY1118143T1 (enExample)
DK (2) DK2485731T3 (enExample)
ES (2) ES2712875T3 (enExample)
HR (1) HRP20160967T1 (enExample)
HU (2) HUE028082T2 (enExample)
IL (4) IL302896A (enExample)
IN (1) IN2012DN03883A (enExample)
LT (1) LT2485731T (enExample)
MX (2) MX353257B (enExample)
PH (1) PH12012500674A1 (enExample)
PL (1) PL2485731T4 (enExample)
PT (1) PT2485731T (enExample)
RS (1) RS55101B1 (enExample)
RU (2) RU2017109664A (enExample)
SI (1) SI2485731T1 (enExample)
SM (1) SMT201600275B (enExample)
TW (1) TWI525093B (enExample)
WO (1) WO2011044157A1 (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG172248A1 (en) 2008-12-19 2011-07-28 Vertex Pharma Pyrazine derivatives useful as inhibitors of atr kinase
MX353257B (es) 2009-10-06 2018-01-05 Millennium Pharmaceuticals Inc Star Compuestos heterociclicos utiles como inhibidores de proteina cinasa-1 dependiente de 3-fosfoinositido (pdk1).
EP2569287B1 (en) 2010-05-12 2014-07-09 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
JP2013529200A (ja) * 2010-05-12 2013-07-18 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用な化合物
MX2012013081A (es) 2010-05-12 2013-05-09 Vertex Pharma Compuestos utiles como inhibidores de cinasa atr.
CA2803687C (en) 2010-07-20 2019-04-30 Vestaron Corporation Insecticidal triazines and pyrimidines
US9181264B2 (en) 2010-09-16 2015-11-10 Hutchison Medipharma Limited Fused heteroaryls and their uses
US8791112B2 (en) 2011-03-30 2014-07-29 Arrien Pharmaceuticals Llc Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
SG10201602515QA (en) 2011-09-30 2016-05-30 Vertex Pharma Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors
PT2940017T (pt) 2011-09-30 2019-10-31 Vertex Pharma Processos para a produção de compostos úteis como inibidores de atr quinase
CN103159741B (zh) * 2011-12-19 2016-08-24 天津市国际生物医药联合研究院 一类酪氨酸激酶抑制剂的制备和用途
NZ700580A (en) 2012-04-05 2016-07-29 Vertex Pharma Compounds useful as inhibitors of atr kinase and combination therapies thereof
CN102627632B (zh) * 2012-04-16 2014-06-18 中国科学院广州生物医药与健康研究院 一种胺基喹唑啉衍生物及其制备方法和用途
CA2869730A1 (en) 2012-04-25 2013-10-31 Takeda Pharmaceutical Company Limited Nitrogenated heterocyclic compound
AU2013259565A1 (en) * 2012-05-08 2014-11-13 Anvyl Llc Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof
EP2873669A4 (en) 2012-07-13 2015-11-25 Takeda Pharmaceutical HETEROCYCLIC CONNECTION
WO2014052669A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
WO2014055756A1 (en) 2012-10-04 2014-04-10 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
US9834520B2 (en) 2013-03-14 2017-12-05 Takeda Pharmaceutical Company Limited Heterocyclic compound
KR20150135332A (ko) 2013-03-14 2015-12-02 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법
EP3006444B1 (en) * 2013-05-31 2017-09-27 Nissan Chemical Industries, Ltd. Heterocyclic amide compound
US10472376B2 (en) 2013-07-03 2019-11-12 Takeda Pharmaceutical Company Limited Amide compound
WO2015002231A1 (ja) 2013-07-03 2015-01-08 武田薬品工業株式会社 複素環化合物
WO2015012328A1 (ja) 2013-07-24 2015-01-29 武田薬品工業株式会社 複素環化合物
CA3148196A1 (en) 2013-10-18 2015-04-23 Celgene Quanticel Research, Inc. Bromodomain inhibitors
WO2015073804A2 (en) * 2013-11-15 2015-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of blocking transmission of malarial parasite
JP6502939B2 (ja) 2013-11-22 2019-04-17 シーエル バイオサイエンシズ リミティド ライアビリティ カンパニー 骨粗鬆症の処置及び予防のためのガストリン拮抗薬
CN104130256B (zh) * 2014-08-01 2016-08-24 上海毕得医药科技有限公司 一种吡啶并[3,4-d]嘧啶-4(3H)-酮衍生物的制备方法
ES2807785T3 (es) * 2014-10-22 2021-02-24 Bristol Myers Squibb Co Compuestos de heteroarilamina bicíclicos como inhibidores de pi3k
AU2015345054B2 (en) 2014-11-14 2020-03-05 Nerviano Medical Sciences S.R.L. 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
CA2992945A1 (en) 2015-07-17 2017-01-26 Memorial Sloan-Kettering Cancer Center Combination therapy using pdk1 and pi3k inhibitors
CN105130980B (zh) * 2015-09-09 2018-05-22 沈阳药科大学 N-3-苯并咪唑噻唑胺类衍生物及其制备方法与应用
WO2017046675A1 (en) * 2015-09-14 2017-03-23 Pfizer Inc. Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors
EP3355926B1 (en) 2015-09-30 2025-12-24 Vertex Pharmaceuticals Inc. Combination of dna damaging agents and atr inhibitors for use in a method for treating cancer using
KR101753652B1 (ko) * 2015-10-21 2017-07-05 한국화학연구원 N-아릴-1h-피라졸로피리딘-3-아민 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 melk 관련 질환의 예방 또는 치료용 약학적 조성물
KR101753654B1 (ko) 2015-10-21 2017-07-05 한국화학연구원 3-(4-(피페라진-1-일)벤즈아미도)-1h-피라졸로피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 melk 관련 질환의 예방 또는 치료용 약학적 조성물
BR112018008025A2 (pt) 2015-10-23 2018-10-23 Sunesis Pharmaceuticals, Inc. inibidores de pdk1 heterocíclicos para uso no trata-mento de câncer
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
HUE064656T2 (hu) 2016-03-28 2024-04-28 Incyte Corp Pirrolotriazin vegyületek mint TAM inhibitorok
AU2017252276A1 (en) 2016-04-18 2018-11-15 Celgene Quanticel Research, Inc. Therapeutic compounds
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US11020398B2 (en) 2016-08-24 2021-06-01 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof
EP3558971B1 (en) 2016-12-22 2022-02-23 Global Blood Therapeutics, Inc. Histone methyltransferase inhibitors
JP6420021B1 (ja) * 2017-03-10 2018-11-07 大塚化学株式会社 反応生成物及びゴム組成物
BR112019025770A2 (pt) * 2017-06-09 2020-06-23 Global Blood Therapeutics, Inc. Compostos de azaindol como inibidores de histona metiltransferase
US20190175589A1 (en) * 2017-11-09 2019-06-13 Sunesis Pharmaceuticals, Inc. Pharmaceutical formulations, processes for preparation, and methods of use
JP7307734B2 (ja) 2018-01-26 2023-07-12 ブリストル-マイヤーズ スクイブ カンパニー キナーゼ阻害剤としてのアミノピロロトリアジン
CN109087534A (zh) * 2018-10-09 2018-12-25 王业宝 一种基于车辆行驶轨迹的交通冲突检测方法
KR102293339B1 (ko) * 2019-04-17 2021-08-25 이화여자대학교 산학협력단 아미노알코올을 포함하는 아민 화합물에 대한 형광 및/또는 원편광 이색성 센서용 신규 프로브 화합물, 및 이를 이용한 형광 및 원편광 이색성 동시 분석 방법
CN110066221B (zh) * 2019-05-16 2022-03-08 海门瑞一医药科技有限公司 一种环丙基甲胺的制备方法
WO2021064141A1 (en) * 2019-10-02 2021-04-08 Tolremo Therapeutics Ag Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
EP4067354B1 (en) * 2019-11-25 2025-10-22 Daewoong Pharmaceutical Co., Ltd. Novel triazolopyridine derivative and pharmaceutical composition comprising same
JP2024502083A (ja) * 2020-12-31 2024-01-17 清華大学 ピリジン-2-アミン誘導体、その医薬組成物、及び使用
AR127972A1 (es) * 2021-12-17 2024-03-13 Pi Industries Ltd Novedosos compuestos de piridina carboxamida bicíclica sustituida fusionada para combatir hongos fitopatogénicos
IL313857A (en) * 2021-12-24 2024-08-01 Psylo Pty Ltd Substances, medicines containing them and their uses
WO2024040242A1 (en) 2022-08-19 2024-02-22 Viracta Therapeutics, Inc. Combinations of pdk1 inhibitors and kinase inhibitors
WO2024040241A1 (en) 2022-08-19 2024-02-22 Viracta Therapeutics, Inc. Pharmaceutical formulations, processes for preparation, and methods of use
WO2024220937A2 (en) * 2023-04-21 2024-10-24 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
CN117603068A (zh) * 2023-08-01 2024-02-27 常州寅盛药业有限公司 一种氨甲环酸的制备方法
WO2025076290A1 (en) * 2023-10-05 2025-04-10 Purdue Research Foundation 5-6-5/6-bisaryl compounds as flt3 inhibitors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3175980A (en) * 1958-05-23 1965-03-30 Geigy Ag J R Compositions of matter of improved appearance in daylight, containing a 3.5-diaminopyrazine-2.6-dicarboxylic acid derivative
PL114780B1 (en) * 1978-03-10 1981-02-28 Inst Przemyslu Farmaceutic Process for preparing novel alkylamides of 2-anilinonicotinic acids
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
DE69907963T2 (de) * 1998-12-23 2004-05-19 Eli Lilly And Co., Indianapolis Heteroaromatische amide als inhibitoren von faktor xa
EP1140881B1 (en) * 1998-12-23 2006-05-17 Eli Lilly And Company Antithrombotic amides
GB0001930D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
CA2484209C (en) 2002-05-03 2013-06-11 Exelixis, Inc. Protein kinase modulators and methods of use
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
WO2005005421A1 (en) 2003-07-08 2005-01-20 Novartis Ag Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
WO2005039564A1 (en) * 2003-10-02 2005-05-06 Vertex Pharmaceuticals Incorporated Phthalimide compounds useful as protein kinase inhibitors
JP2007509173A (ja) * 2003-10-24 2007-04-12 シエーリング アクチエンゲゼルシャフト インドリノン誘導体類及び疾病状態、例えば癌の処理へのそれらの使用
AR049418A1 (es) * 2004-02-27 2006-08-02 Bayer Pharmaceuticals Corp Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
SE0401345D0 (sv) * 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine as scaffold
EP1655297A1 (en) * 2004-11-03 2006-05-10 Schering Aktiengesellschaft Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
WO2006133006A2 (en) 2005-06-03 2006-12-14 Bayer Healthcare Ag 1-methyl-1h-pyrazole-4-carboxamides useful as cancer chemotherapeutic agents
US7572808B2 (en) 2005-06-17 2009-08-11 Bristol-Myers Squibb Company Triazolopyridine cannabinoid receptor 1 antagonists
US7547782B2 (en) * 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
JP5116687B2 (ja) 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ[2,1−f][1,2,4]トリアジン−4−イルアミンIGF−1Rキナーゼ阻害剤
JP2009523812A (ja) * 2006-01-19 2009-06-25 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド 融合へテロ二環式キナーゼ阻害剤
EP2049119A2 (en) * 2006-06-29 2009-04-22 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morphoolin-4-ylmethyl-1h-benzoimidazol-2-yl)-1h-1-pyrazol-4-yl]-urea
US8778977B2 (en) * 2006-06-30 2014-07-15 Sunesis Pharmaceuticals, Inc. Pyridinonyl PDK1 inhibitors
WO2008016643A2 (en) 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
US7915287B2 (en) * 2006-12-20 2011-03-29 Amgen Inc. Substituted heterocycles and methods of use
SI2139882T1 (sl) * 2007-03-23 2014-03-31 Amgen Inc. 3-substituirani kinolinski ali kinoksalinski derivati in njihoba uporaba kot inhibitorji fosfatidilinozitol 3-kinaze (pi3k)
ES2395581T3 (es) * 2007-06-20 2013-02-13 Merck Sharp & Dohme Corp. Inhibidores de quinasas janus
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
BRPI1010882A2 (pt) * 2009-06-08 2019-09-24 California Capital Equity Llc derivados de triazina e suas aplicações terapêuticas.
MX353257B (es) 2009-10-06 2018-01-05 Millennium Pharmaceuticals Inc Star Compuestos heterociclicos utiles como inhibidores de proteina cinasa-1 dependiente de 3-fosfoinositido (pdk1).

Similar Documents

Publication Publication Date Title
JP2013506715A5 (enExample)
RU2012118667A (ru) Гетероциклические соединения, используемые в качестве ингибиторов pdk1
Mokale et al. Synthesis and anti-inflammatory activity of some 3-(4, 6-disubtituted-2-thioxo-1, 2, 3, 4-tetrahydropyrimidin-5-yl) propanoic acid derivatives
AU2015355839B2 (en) Heterocyclic derivatives and use thereof
JP2015532295A5 (enExample)
JP2013503905A5 (enExample)
JP2016509047A5 (enExample)
JP2014503567A5 (enExample)
BR112013026137B1 (pt) pirimidinil-pirróis substituídos ativos como inibidores da quinase
RU2010147404A (ru) Замещенные дигидропиразолоны в качестве ингибиторов hif-пролил-4-гидроксилазы
US8822732B2 (en) 1,5-diphenyl-penta-1,4-dien-3-one compounds
JP2009530424A5 (enExample)
KR20130099064A (ko) (아자)인돌리진 유도체 및 그 의약용도
JP2024515062A (ja) 重水素化dhodh阻害剤
JP2024096821A (ja) 癌または炎症性疾患の治療のためのヘテロ二環式カルボキシ酸
KR101648377B1 (ko) 축합환 유도체 및 그 의약용도
JP2010510216A5 (enExample)
JPWO2005080322A1 (ja) フルオレン誘導体
AU2012236275B2 (en) Derivatives of sulindac, use thereof and preparation thereof
JP2018538244A5 (enExample)
JP2025500176A (ja) カルボン酸バイオアイソスタを含むdhodh阻害剤
DK168861B1 (da) 4-methyl-5-(2-(4-phenyl-1-piperazinyl)ethyl)thiazolderivater og fremgangsmåde til fremstilling deraf, farmaceutiske midler indeholdende thiazolderivaterne og fremgangsmåde til fremstilling deraf og anvendelse af derivaterne til fremstilling af lægemidler
JP5302214B2 (ja) Trpv1受容体拮抗薬としてのo−置換ジベンジル尿素誘導体
EP3980413B1 (en) Heterocyclic immunomodulators as pdl1 checkpoint inhibitor
JP7101359B2 (ja) Pd-l1発現抑制作用を有する新規化合物